Weight-loss injections vs pills: every FDA-approved option in each group, trial results, side effects, daily-life differences and self-pay prices checked October 6, 2026.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- FDA-approved weight-management injections include Wegovy and Zepbound (weekly) and Saxenda (daily); approved long-term pills include the Wegovy pill, Foundayo, Qsymia, Contrave and orlistat.[15]
- Average weight loss in the main placebo-controlled trials ranged from about 5% (Contrave) to 21% (Zepbound 15 mg); trials were separate, so this is not a ranking.[7]
- Semaglutide is approved as both a weekly injection (-14.9% in STEP 1) and a daily pill (-13.6% in OASIS 4).[9]
- Side effects depend on drug type more than on form: GLP-1 pills and shots share digestive effects and class warnings.[1]
- Medicare's temporary GLP-1 Bridge (July 2026 to December 2027) covers Wegovy, Zepbound KwikPen and Foundayo for weight with a $50 copay for people who meet its criteria.[21]
The short answer
FDA-approved weight-management injections (Wegovy, Zepbound, Saxenda) and long-term pills (Wegovy pill, Foundayo, Qsymia, Contrave, orlistat) differ in how often they are taken, food rules, needles, side effects, other approved uses and price. Average weight loss in their main trials ranged from about 5% to 21%; trials were separate, so this is not a ranking.
Scorecards
| Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | Wegovy Pill (oral semaglutide): status, how it is taken, how it comparesFDA approved for weight managementPrescriptionPill | |
|---|---|---|
| Medical supervision | Required | — |
No overall score and no winner: what matters depends on you. Hover a value for its definition.
Facts side by side
| Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | Wegovy Pill (oral semaglutide): status, how it is taken, how it comparesFDA approved for weight managementPrescriptionPill | |
|---|---|---|
| Purpose | Reduce excess body weight and maintain weight reduction long term (with reduced-calorie diet and increased physical activity); Reduce excess body weight and maintain weight reduction long term (injection); Reduce the risk of major adverse cardiovascular events (CV death, nonfatal heart attack, nonfatal stroke); Noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3), accelerated approval (injection); Weight reduction and maintenance, and cardiovascular risk reduction (Wegovy tablets) | Reduce excess body weight and maintain weight reduction long term (with reduced-calorie diet and increased physical activity); Reduce the risk of major adverse cardiovascular events |
| Class or type | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Regulatory status | FDA approved for weight managementPrescriptionInjection | FDA approved for weight managementPrescriptionPill |
| Prescription required | Yes | Yes |
| How it works | Wegovy (semaglutide): FDA-approved uses, who the label covers, how it is taken in general, trial results, side effects, boxed warning and dated prices. | The Wegovy pill (oral semaglutide) is FDA approved for adults: approval, how the label says to take it, OASIS 4 results, pill vs injection and self-pay prices. |
| How it is done or taken | Injection | Pill (tablet) |
| How often | Weekly | Daily |
| Average outcomes in studies |
|
|
| Main risks |
|
|
| Cost (dated) | from 25 USD per month with commercial coverage (max savings $100 a month; government beneficiaries excluded) (checked October 6, 2026) | from 149 USD per month, 1.5 mg (30 tablets), NovoCare Pharmacy (checked October 6, 2026) |
| Official resources | dailymed.nlm.nih.gov | dailymed.nlm.nih.gov |
What the trials showed
- No injection-vs-pill trial in obesity found Same-drug comparison only across separate trials: semaglutide 2.4 mg injection -14.9% at 68 weeks (STEP 1) and semaglutide 25 mg pill -13.6% at 64 weeks (OASIS 4).[9]
- SURMOUNT-5 (injection vs injection) 751 adults, 72 weeks, open label: tirzepatide -20.2% vs semaglutide -13.7%.[10]
Side effects compared
| Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | Wegovy Pill (oral semaglutide): status, how it is taken, how it comparesFDA approved for weight managementPrescriptionPill | |
|---|---|---|
| From the label |
|
|
Cost and coverage
Prices change often and depend on pharmacy, plan and location. Insurance can change what you pay. Every price shows the date we checked it.
Things people weigh up
- Needles vs daily routine: injections are mostly weekly; pills are daily, and the Wegovy pill has empty-stomach rules.
- Average results differ by medicine more than by form; the weekly injections and GLP-1 pills had the largest averages in their own trials.
- Side effects depend on drug type: GLP-1 pills and shots share digestive effects; Qsymia, Contrave and orlistat have different profiles and rules.
- Other approved uses (heart risk, sleep apnea, MASH, teens) belong to specific medicines.
- Self-pay prices overlap (about $75 to $449 a month by medicine and strength, checked 2026-10-06); coverage varies by plan.
- Medicare's temporary GLP-1 Bridge covers Wegovy (both forms), Zepbound KwikPen and Foundayo, not the older pills.
These are the differences people commonly consider, not a recommendation. A clinician can help you decide what fits you.
In short: As of October 6, 2026, the FDA-approved weight-management injections for obesity in general are Wegovy and Zepbound (weekly) and Saxenda (daily, being discontinued). The approved long-term pills are the GLP-1 pills Wegovy pill and Foundayo, plus the non-GLP-1 pills Qsymia, Contrave and orlistat. In their main placebo-controlled trials, average weight loss ranged from about 5% to 21% depending on the medicine, with the weekly injections and the GLP-1 pills toward the top of that range. Pills avoid needles but are taken every day, and some have strict food rules; injections are weekly but need pens and refrigeration. There is no single right answer: the choice depends on your health, preferences, coverage and a clinician’s evaluation.
Until recently, “injection or pill” meant choosing between very different levels of effect. Two FDA approvals changed that: the Wegovy pill (oral semaglutide, December 22, 2025) and Foundayo (orforglipron, April 1, 2026). This page lays out the approved options in both groups, what trials showed, side effects, practical differences and dated prices, so you can research and then talk it through with a licensed clinician.
Injections vs pills at a glance
- 3 injections, 5 long-term pillsFDA-approved options for chronic weight management in obesity in general (Imcivree, an injection, is only for rare genetic conditions; orlistat is also sold over the counter as Alli)FDA labels
- -20.9%average weight change with Zepbound 15 mg at 72 weeks (SURMOUNT-1), the largest in this group's main trialsNEJM 2022
- -13.6%average weight change with the Wegovy pill 25 mg at 64 weeks (OASIS 4), the largest among pillsNEJM 2025
Checked on October 6, 2026
The approved options in each group
| Medicine | Form and schedule | Type | Other approved uses |
|---|---|---|---|
| Zepbound (tirzepatide) | Injection, weekly (pens, vials, KwikPen) | GIP and GLP-1 receptor agonist | Moderate to severe obstructive sleep apnea in adults with obesity |
| Wegovy (semaglutide) | Injection, weekly (Wegovy HD 7.2 mg for some adults) | GLP-1 receptor agonist | Heart-risk reduction; MASH; teens 12+ |
| Saxenda (liraglutide) | Injection, daily; being discontinued (last shipments late January 2027); generic liraglutide approved 2025 | GLP-1 receptor agonist | Teens 12+ over 60 kg |
| Wegovy pill (semaglutide) | Tablet, daily, empty stomach, wait 30 minutes | GLP-1 receptor agonist | Heart-risk reduction (adults) |
| Foundayo (orforglipron) | Tablet, daily, with or without food | GLP-1 receptor agonist (non-peptide) | None beyond weight (adults) |
| Qsymia (phentermine-topiramate) | Capsule, once each morning | Appetite suppressant plus anti-seizure medicine; Schedule IV | Teens 12+ with obesity |
| Contrave (naltrexone-bupropion) | Tablets, twice daily at full dose | Opioid blocker plus antidepressant | None beyond weight (adults) |
| Orlistat (Xenical; Alli over the counter) | Capsule with each fat-containing meal | Lipase inhibitor (blocks some fat absorption) | Xenical: teens 12+ |
Most of these labels describe adults with obesity, or overweight with at least one weight-related condition, used with a reduced-calorie diet and more activity. Full details and status badges are on the weight-loss injections hub, the weight-loss pills hub and the medications hub.
Teens. For adolescents 12 and older with obesity, the approved options are the Wegovy injection, Saxenda (over 60 kg), Qsymia and prescription orlistat (Xenical). Neither GLP-1 pill and neither Zepbound nor Contrave is approved for people under 18. Decisions for teens belong with a pediatric clinician.
What the main trials showed
Each medicine was tested mainly against placebo, in different trials, years apart, with different people and lengths. So the chart below shows the range of results, not a ranking. Only a few head-to-head trials exist, and none compares an injection with a pill in obesity.
| Item | Medicine | Placebo |
|---|---|---|
| Zepbound 15 mg, injection (SURMOUNT-1, 72 wk) | 20.9% | 3.1% |
| Wegovy 2.4 mg, injection (STEP 1, 68 wk) | 14.9% | 2.4% |
| Wegovy pill 25 mg (OASIS 4, 64 wk) | 13.6% | 2.2% |
| Foundayo top dose, pill (ATTAIN-1, 72 wk) | 11.1% | 2.1% |
| Qsymia 15/92 mg, capsule (Study 2, 1 yr) | 9.8% | 1.2% |
| Saxenda 3 mg, injection (Study 1, 56 wk) | 7.4% | 3% |
| Contrave, tablet (COR-I, 56 wk) | 5.4% | 1.3% |
Separate trials; not a ranking. Orlistat (XENDOS, 4 years): -5.2% vs -2.8%. Individual results vary widely.
Source: SURMOUNT-1, STEP 1 and OASIS 4 (NEJM); Foundayo, Qsymia, Saxenda and Contrave prescribing information (checked on October 6, 2026)
The head-to-head trials that do exist compare within a form. SURMOUNT-5 compared two injections (tirzepatide -20.2% versus semaglutide -13.7% at 72 weeks); STEP 8 compared weekly semaglutide with daily liraglutide (-15.8% versus -6.4%); ACHIEVE-3 compared two pills in type 2 diabetes. See Wegovy vs Zepbound, Wegovy vs Saxenda and Wegovy vs Foundayo.
Same drug, two forms. Semaglutide is the one medicine approved for weight as both a weekly injection and a daily pill. In their own trials, the 2.4 mg injection led to -14.9% at 68 weeks and the 25 mg pill to -13.6% at 64 weeks. The pill needs a much larger daily dose because only a small fraction is absorbed from the stomach, which is why the empty-stomach rules matter.
Side effects: by drug type, not by form
Side effects depend mostly on how a medicine works, not on whether it is swallowed or injected. GLP-1 pills and GLP-1 injections share the same digestive side effects and the same class warnings (including the thyroid C-cell tumor boxed warning). The non-GLP-1 pills have quite different profiles.
| Group | Typical side effects | Key safety points on the labels |
|---|---|---|
| GLP-1 and GIP/GLP-1 injections and pills | Nausea, diarrhea, vomiting, constipation, mostly while doses increase | Thyroid C-cell tumor boxed warning; pancreatitis; gallbladder disease; low blood sugar with insulin or sulfonylureas; dehydration and kidney injury; aspiration during anesthesia |
| Qsymia | Tingling, dry mouth, constipation, altered taste, insomnia, dizziness | Birth defects: pregnancy tests and REMS; controlled substance; mood, thinking and eye effects; taper to stop |
| Contrave | Nausea, constipation, headache, vomiting, dizziness | Boxed warning on suicidal thoughts; seizures; blood pressure; not with opioids |
| Orlistat | Oily spotting, gas with discharge, urgency, fatty stools | Take a multivitamin at a separate time; rare liver injury and kidney problems on the label |
For the GLP-1 class, see GLP-1 side effects; for the other pills, appetite suppressants and Contrave vs Qsymia.
Everyday differences
| Weekly injections | Daily GLP-1 pills | Other pills | |
|---|---|---|---|
| How often | Once a week (Saxenda: daily) | Once a day | Once or twice a day; orlistat with meals |
| Needles | Yes, under the skin | No | No |
| Food and timing rules | Any time of day, with or without meals | Wegovy pill: empty stomach, up to 4 oz water, wait 30 minutes. Foundayo: with or without food | Contrave: avoid high-fat meals with doses. Orlistat: with fat-containing meals |
| Storage | Pens are kept in the refrigerator before use; each label lists its room-temperature limits | See the label’s storage section | See each label |
| Missed dose | Each label has a window for a late dose | Wegovy pill: skip and take the next day; Foundayo: take as soon as possible, never double | See each label |
| Interactions to ask about | Slower stomach emptying can affect oral medicines; Zepbound and birth-control pills | Wegovy pill: timing with other morning pills; Foundayo: birth-control pills, CYP3A4 medicines | Contrave: opioids, antidepressants; Qsymia: birth-control pills, sedatives; orlistat: cyclosporine, levothyroxine timing |
Researching injection vs pill: a simple path
- Know your numbersCheck your BMI with the calculator and list your health conditions and medicines.
- List what matters to youNeedles, food rules, daily vs weekly, cost, other conditions such as heart disease or sleep apnea.
- Read the labelsUse the medicine pages here and the official prescribing information they link to.
- Check coverageAsk your plan what it covers and whether prior authorization applies.
- Get evaluatedBook a visit with a licensed clinician and bring your questions.
Cost and coverage (checked on October 6, 2026)
Self-pay prices from the manufacturers vary by strength. The chart shows each medicine’s lowest to highest regular monthly self-pay price from its maker’s own program (introductory offers are noted separately).
| Item | Low | High |
|---|---|---|
| Zepbound KwikPen or vial (on-time refills) | $299 | $449 |
| Wegovy pen and HD pen | $349 | $399 |
| Wegovy pill | $149 | $299 |
| Foundayo pill (regular prices) | $149 | $349 |
| Contrave (CurAccess, or less) | $99 | $99 |
| Qsymia (home delivery, 30-day) | $74.99 | $74.99 |
Wegovy pen intro $199 (first 2 fills of starting strengths, new patients, through 12/31/2026). Zepbound higher strengths $499-$699 without on-time refills. Foundayo temporary prices through 12/31/2026. No manufacturer self-pay price found for Saxenda.
Source: Lilly (Zepbound, Foundayo), NovoCare Pharmacy (Wegovy), contrave.com, qsymia.com (checked on October 6, 2026)
- Commercial insurance. Coverage for weight-management medicines varies widely. In KFF’s 2025 employer survey, 43% of firms with 5,000 or more workers covered GLP-1s for weight loss, compared with 16% of firms with 200 to 999 workers. Makers’ savings cards (from $25 a month) only help if your plan covers the drug.
- Medicare. Medicare is barred by law from covering drugs used for weight loss, but the temporary Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy (injection and tablets), Zepbound KwikPen and Foundayo for weight management with a $50 copay for people who meet its criteria. Qsymia, Contrave and Saxenda are not on the Bridge list.
- Medicaid. 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026, according to KFF.
Full details: does insurance cover GLP-1s?, Wegovy cost, Zepbound cost and the GLP-1 cost comparison tool.
What to avoid with either form
Compounded GLP-1 injections and pills, “research-use” peptides and products sold without a prescription are not FDA approved, and the FDA has warned about counterfeit semaglutide in the U.S. supply chain. Supplements marketed as “natural GLP-1” are not GLP-1 medicines. Read compounded GLP-1s and our supplements hub before buying anything online.
Long term, with either form
Weight tends to return when these medicines stop: in STEP 4 (semaglutide injection) people switched to placebo regained 6.9% over 48 weeks, and in SURMOUNT-4 (tirzepatide injection) 14.0% over a year. Protein, strength training and follow-up matter at every stage; see life after a GLP-1, muscle loss on GLP-1s and the protein calculator. Not sure where to start? Find My Options shows the categories that match your preferences.
Compared with the items
FDA approved for weight managementPrescriptionInjectionWegovy (semaglutide): uses, side effects, cost and FDA statusSemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for weight managementPrescriptionPillWegovy Pill (oral semaglutide): status, how it is taken, how it comparesSemaglutide: one ingredient, several brands · Pill (tablet) · DailyRelated comparisons
Related guides
Weight-Loss Injections: GLP-1 and dual-agonist shots explainedWeight-loss injections explained: which shots are FDA approved for weight vs diabetes, weekly vs daily, using…
Weight-Loss Pills: prescription, over-the-counter and supplements, by evidenceWeight-loss pills by evidence: FDA-approved prescription pills (Wegovy pill, Foundayo, Qsymia, Contrave, orlistat, phentermine), Alli over…
Oral GLP-1 Pills: Wegovy pill, Foundayo, Rybelsus and Ozempic tablets comparedOral GLP-1 pills compared: Wegovy pill, Foundayo, Rybelsus and Ozempic tablets, with FDA status, label rules,…
GLP-1 Side Effects: common, serious and how they are managedGLP-1 side effects from the FDA labels: common digestive effects by brand, serious risks, the thyroid…Tools for this topic
Questions to ask a professional
- Given my health and other medicines, which medicines in either group could be safe for me?
- Would a weekly injection or a daily pill fit my routine better, and what food rules apply?
- Do I have a condition, such as heart disease or sleep apnea, that makes a specific medicine more relevant?
- What does my insurance cover, and what would each option cost me per month?
- How will we judge whether it is working, and what is the plan if it is not?
- What is the long-term plan, including protein, strength training and stopping?
Frequently asked questions
Are weight-loss pills as effective as injections?
It depends on the medicine. In their own trials, the Wegovy pill (-13.6%) and Foundayo (-11.1%) came close to the Wegovy injection (-14.9%); Zepbound injection (-20.9%) had the largest average. Older pills such as Qsymia and Contrave had smaller averages. These were separate trials, not a direct comparison.
Is there a GLP-1 pill for weight loss?
Yes. The FDA approved the Wegovy pill (oral semaglutide) on December 22, 2025 and Foundayo (orforglipron) on April 1, 2026 for weight management in adults.
Do pills have fewer side effects than injections?
Not necessarily. GLP-1 pills and GLP-1 injections share the same digestive side effects and warnings. Non-GLP-1 pills such as Qsymia and Contrave have different side effects and their own warnings.
Which is cheaper, a pill or an injection?
Prices overlap. On 2026-10-06, manufacturer self-pay prices were about $75 to $99 a month for Qsymia and Contrave programs, $149 to $349 for the GLP-1 pills by strength, and $299 to $449 for Zepbound and $349 to $399 for Wegovy pens. Your cost depends on coverage.
Can I switch from an injection to a pill?
Sometimes, but it is a prescriber decision. The Wegovy label includes instructions for switching between its injection and tablets; moving to a different medicine follows that medicine's label.
Why does the Wegovy pill have to be taken on an empty stomach?
Semaglutide is a peptide that is poorly absorbed from the stomach. The label says to take it in the morning on an empty stomach with up to 4 ounces of water and wait at least 30 minutes before eating, drinking or taking other oral medicines.
Does Medicare cover weight-loss pills?
Medicare is barred by law from covering drugs used for weight loss. The temporary GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers the Wegovy pill and Foundayo, plus Wegovy and Zepbound KwikPen injections, for people who meet its criteria. Qsymia, Contrave and orlistat are not included.
Are compounded GLP-1 pills or drops a safe alternative?
Compounded GLP-1 products are not FDA approved, and the FDA has raised concerns about unapproved versions and counterfeits. Read our compounded GLP-1 guide and talk with a clinician before considering any product.
References
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- ZEPBOUND (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- SAXENDA (liraglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 6, 2026) Drug label
- FOUNDAYO (orforglipron) tablets: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- QSYMIA (phentermine and topiramate) extended-release capsules: prescribing information. Vivus, via DailyMed, 2026. (accessed October 6, 2026) Drug label
- CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets: prescribing information. Nalpropion Pharmaceuticals, via DailyMed, 2025. (accessed October 6, 2026) Drug label
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. doi:10.1056/NEJMoa2206038 · PMID 35658024 · NCT04184622 (accessed October 7, 2026) Randomized trial
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
- Wharton S, Lingvay I, Bogdanski P, et al.. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2500969 · PMID 40934115 · NCT05564117 (accessed October 6, 2026) Randomized trial
- Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2416394 · PMID 40353578 · NCT05822830 (accessed October 6, 2026) Randomized trial
- Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA, 2022. doi:10.1001/jama.2021.23619 · PMID 35015037 · NCT04074161 (accessed October 6, 2026) Randomized trial
- Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021. doi:10.1001/jama.2021.3224 · PMID 33755728 · NCT03548987 (accessed October 7, 2026) Randomized trial
- Aronne LJ, Sattar N, Horn DB, et al.. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. doi:10.1001/jama.2023.24945 · PMID 38078870 · NCT04660643 (accessed October 7, 2026) Randomized trial
- Drugs@FDA: Wegovy tablets, NDA 218316. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
- Drugs@FDA: Foundayo, NDA 220934. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
- Zepbound coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Foundayo coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- Contrave savings and CurAccess pharmacy. Currax Pharmaceuticals. (accessed October 6, 2026) Other
- Qsymia pricing and home delivery. Vivus. (accessed October 6, 2026) Other
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
- 2025 Employer Health Benefits Survey. KFF, 2025. (accessed October 6, 2026) Other
- Medicaid Coverage of and Spending on GLP-1s. KFF, 2026. (accessed October 6, 2026) Other
- What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries. KFF, 2026. (accessed October 6, 2026) Other
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.